Aethlon Medical

Aethlon Medical is a clinical-stage biotech focused on developing its proprietary Hemopurifier® device, a lectin-affinity blood filter designed as an adjunctive therapy to remove immunosuppressive exosomes in cancer and enveloped viruses in infections. Its key achievements include securing dual FDA Breakthrough Device designations and advancing an ongoing safety and feasibility trial in oncology patients in Australia. The company's strategy leverages this regulatory pathway to accelerate development in two high-need areas, aiming to validate a platform that could enhance the efficacy of existing immunotherapies and provide a rapid-response tool for pandemic threats.

The Hemopurifier® is a lectin-affinity based blood filtration device designed to selectively remove specific glycosylated targets from circulation, including immunosuppressive tumor-derived exosomes in cancer and enveloped viruses in infectious disease.

Aethlon faces limited direct competition, with its primary differentiation being an FDA Breakthrough Device for exosome depletion in cancer. In infectious disease, it competes with other broad-spectrum blood purification devices like ExThera's Seraph® 100, but targets a distinct viral indication.